Preventive behaviors and behavioral risk factors among gynecologic cancer survivors: Results from the 2020 Behavioral Risk Factor Surveillance System Survey.
cervical cancer
ovarian cancer
physical activity
preventive behaviors
rural residence
smoking
uterine cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
10
05
2023
received:
17
02
2022
accepted:
14
05
2023
medline:
14
8
2023
pubmed:
30
6
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
Maintaining a healthy lifestyle is an important factor in promoting positive outcomes for gynecologic cancer survivors. We examined preventive behaviors among gynecologic cancer survivors (n = 1824) and persons without a history of cancer in a cross-sectional analysis, using data from the 2020 Behavioral Risk Factor Surveillance System survey (BRFSS). BRFSS is a cross-sectional telephone-based survey of U.S. residents 18 years of age and older, which collects information about health-related factors and use of preventive services. The prevalence rates of colorectal cancer screening were respectively 7.9 (95% CI: 4.0-11.9) and 15.0 (95% CI: 4.0-11.9) %-points higher among gynecologic and other cancer survivors compared to that of 65.2% among those without any history of cancer. However, no differences were observed in breast cancer screening between gynecologic cancer survivors (78.5%) and respondents without any history of cancer (78.7%). Coverage of influenza vaccination among gynecologic cancer survivors were 4.0 (95% CI: 0.3-7.6) %-points higher than that of the no cancer group, but 11.6 (95% CI: 7.6-15.6) %-points lower than that of the other cancer group. Pneumonia vaccination rate among gynecologic cancer survivors, however, was not statistically different than that of other cancer survivors and respondents with no history of cancer. When examining modifiable risk behaviors, the prevalence of smoking among gynecologic cancer survivors was 12.8 (95% CI: 9.5-16.0) and 14.2 (95% CI: 10.8-17.7) %-points higher than smoking prevalence among other cancer survivors and respondents without any history of cancer. The rate differentials were even higher in rural areas, 17.4 (95% CI: 7.2-27.6) and 18.4 (95% CI: 7.4-29.4) %-points respectively. There were no differences in the prevalence of heavy drinking across the groups. Lastly, gynecologic and other cancer survivors were less likely to be physically active (Δ = -12.3, 95% CI: -15.8 to -8.8 and Δ = -6.9, 95% CI: -8.5 to -5.3, respectively) than those without any history of cancer. Smoking prevalence among gynecologic cancer survivors is alarmingly high. Intervention studies are needed to identify effective ways to assist gynecologic cancer survivors to quit smoking and refrain from hazardous alcohol consumption. In addition, women with gynecologic malignancies should made aware of the importance of physical activity.
Sections du résumé
BACKGROUND
Maintaining a healthy lifestyle is an important factor in promoting positive outcomes for gynecologic cancer survivors.
METHODS
We examined preventive behaviors among gynecologic cancer survivors (n = 1824) and persons without a history of cancer in a cross-sectional analysis, using data from the 2020 Behavioral Risk Factor Surveillance System survey (BRFSS). BRFSS is a cross-sectional telephone-based survey of U.S. residents 18 years of age and older, which collects information about health-related factors and use of preventive services.
RESULTS
The prevalence rates of colorectal cancer screening were respectively 7.9 (95% CI: 4.0-11.9) and 15.0 (95% CI: 4.0-11.9) %-points higher among gynecologic and other cancer survivors compared to that of 65.2% among those without any history of cancer. However, no differences were observed in breast cancer screening between gynecologic cancer survivors (78.5%) and respondents without any history of cancer (78.7%). Coverage of influenza vaccination among gynecologic cancer survivors were 4.0 (95% CI: 0.3-7.6) %-points higher than that of the no cancer group, but 11.6 (95% CI: 7.6-15.6) %-points lower than that of the other cancer group. Pneumonia vaccination rate among gynecologic cancer survivors, however, was not statistically different than that of other cancer survivors and respondents with no history of cancer. When examining modifiable risk behaviors, the prevalence of smoking among gynecologic cancer survivors was 12.8 (95% CI: 9.5-16.0) and 14.2 (95% CI: 10.8-17.7) %-points higher than smoking prevalence among other cancer survivors and respondents without any history of cancer. The rate differentials were even higher in rural areas, 17.4 (95% CI: 7.2-27.6) and 18.4 (95% CI: 7.4-29.4) %-points respectively. There were no differences in the prevalence of heavy drinking across the groups. Lastly, gynecologic and other cancer survivors were less likely to be physically active (Δ = -12.3, 95% CI: -15.8 to -8.8 and Δ = -6.9, 95% CI: -8.5 to -5.3, respectively) than those without any history of cancer.
CONCLUSION
Smoking prevalence among gynecologic cancer survivors is alarmingly high. Intervention studies are needed to identify effective ways to assist gynecologic cancer survivors to quit smoking and refrain from hazardous alcohol consumption. In addition, women with gynecologic malignancies should made aware of the importance of physical activity.
Identifiants
pubmed: 37387412
doi: 10.1002/cam4.6134
pmc: PMC10417268
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15435-15446Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Public Health (Oxf). 2018 Mar 1;40(1):129-137
pubmed: 28334835
J Cancer Surviv. 2022 Oct 10;:
pubmed: 36217067
Vital Health Stat 2. 2012 Jan;(154):1-65
pubmed: 22783637
Int J Womens Health. 2016 May 23;8:151-67
pubmed: 27284267
J Cancer Surviv. 2017 Apr;11(2):233-245
pubmed: 27837443
Support Care Cancer. 2018 Dec;26(12):4087-4096
pubmed: 29934683
JAMA. 2021 Jun 8;325(22):2312-2314
pubmed: 34100876
Am J Prev Med. 2022 Sep;63(3):431-439
pubmed: 35469700
Disabil Rehabil. 2013;35(24):2038-45
pubmed: 23772995
Cancer Med. 2023 Jul;12(14):15435-15446
pubmed: 37387412
J Cancer Surviv. 2013 Mar;7(1):93-103
pubmed: 23212604
Cancer Med. 2019 Nov;8(16):7123-7132
pubmed: 31568695
Maturitas. 2018 May;111:82-89
pubmed: 29673836
J Clin Oncol. 2006 Nov 10;24(32):5125-31
pubmed: 17093274
Am J Clin Oncol. 2017 Oct;40(5):451-457
pubmed: 25784565
Obstet Gynecol Surv. 2019 Nov;74(11):679-692
pubmed: 31755545
Prev Med. 2005 Jun;40(6):702-11
pubmed: 15850868
Eur J Cancer Care (Engl). 2018 Jan;27(1):
pubmed: 28940854
Cancer Causes Control. 2013 Aug;24(8):1481-90
pubmed: 23677333
Gynecol Oncol. 2021 Oct;163(1):22-28
pubmed: 34400004
Cancer Med. 2018 Dec;7(12):6331-6339
pubmed: 30358141
J Environ Health Sci. 2019;5(2):90-92
pubmed: 32104722
BMJ Open. 2018 Mar 27;8(3):e020313
pubmed: 29593021
Psychooncology. 2017 Aug;26(8):1099-1104
pubmed: 27665487
Gynecol Oncol. 2022 Jun;165(3):405-409
pubmed: 35437169
J Clin Oncol. 2009 Feb 20;27(6):986-93
pubmed: 19075281
J Womens Health (Larchmt). 2015 Nov;24(11):899-906
pubmed: 26208166
Int J Gynecol Cancer. 2015 Sep;25(7):1285-91
pubmed: 25966932
Am J Prev Med. 2018 Dec;55(6):830-838
pubmed: 30352719